Atomo Diagnostics Limited (AT1) Fair Value & Analysis
Healthcare · AU · Market cap A$16.2M
Fair value as of: Jun 24, 2026
From 2 valuation models · updated 5 days ago
Share price −15.0% over the past month.
Price vs Fair Value (12 months)
12‑month range A$0.0140 – A$0.0440 · fair‑value band A$0.0300 – A$0.0400 · the A$0.0170 price screens below the A$0.0300 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Atomo Diagnostics Limited (AT1) currently trades at A$0.0170, while our model-based Fair Value estimate is A$0.0300 — implying the stock looks roughly 76.5% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
Trailing-twelve-month revenue stands at A$3.9M. Revenue grew 6.2% year over year. It earns a return on equity of -56.6%. The balance sheet holds a net cash position of A$3.0M. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Atomo Diagnostics Limited engages in the development and sale of medical devices worldwide. The company offers blood test devices, such as Pascal, Curie, Galileo, Elion, and Florey under the AtomoRapid brand. It also offers HIV Rapid self-Test device; and digital health solutions. Atomo Diagnostics Limited was incorporated in 2010 and is headquartered in Leichhardt, Australia.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Atomo Diagnostics Limited reported revenue of A$3.8M in FY2025 versus A$6.7M in FY2021, a compound −13.3%/yr. Reported net income was −A$5.0M in FY2025.
Open the full interactive analysis →
Similar stocks
6 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | 1,600 MXN | 1,228 MXN | -23% |
| Stryker Corporation S1YK34 | R$79.21 | R$43.74 | -45% |
| Medtronic plc MDT | $81.67 | $60.02 | -27% |
| Boston Scientific Corporation B1SX34 | R$229.30 | R$43.33 | -81% |
| Edwards Lifesciences Corporation EW | $85.98 | $41.02 | -52% |
| Siemens Healthineers AG SEMHF | $39.95 | $44.36 | +11% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Atomo Diagnostics Limited (AT1) undervalued?
What is the fair value of AT1?
What is the quality score of AT1?
What is the revenue of Atomo Diagnostics Limited (AT1)?
What is the net profit margin of AT1?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.